Frontiers in Pharmacology (Jan 2022)

Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging

  • Leanne De Silva,
  • Ju-Yen Fu,
  • Thet Thet Htar,
  • Wan Hamirul Bahrin Wan Kamal,
  • Azahari Kasbollah,
  • Saravanan Muniyandy,
  • Lay-Hong Chuah

DOI
https://doi.org/10.3389/fphar.2021.778396
Journal volume & issue
Vol. 12

Abstract

Read online

The purpose of this work was to study the biodistribution of niosomes in tumor-implanted BALB/c mice using gamma scintigraphy. Niosomes were first formulated and characterized, then radiolabeled with Technetium-99 m (99mTc). The biodistribution of 99mTc-labeled niosomes was evaluated in tumor-bearing mice through intravenous injection and imaged with gamma scintigraphy. The labeled complexes possessed high radiolabeling efficiency (98.08%) and were stable in vitro (>80% after 8 h). Scintigraphic imaging showed negligible accumulation in the stomach and thyroid, indicating minimal leaching of the radiolabel in vivo. Radioactivity was found mainly in the liver, spleen and kidneys. Tumor-to-muscle ratio indicated a higher specificity of the formulation for the tumor area. Overall, the formulated niosomes are stable both in vitro and in vivo, and show preferential tumor accumulation.

Keywords